By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.




CEO: John F. Milligan, PhD

Chief Scientific Officer: Norbert W. Bischofberger, PhD

CFO: Robin L. Washington

COO: Kevin Young


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Gilead
Employees: 4,000
Symbol: GILD

Company News
3 Things Gilead (GILD)' CEO Just Said That You'll Want to Know 2/23/2017 6:46:00 AM
Sarepta (SRPT) Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead (GILD) for $125 Million 2/21/2017 5:52:30 AM
Why Investors Are Betting Big Against Gilead (GILD)'s Possible Acquisition Candidate Intercept Pharma (ICPT) 2/17/2017 6:53:18 AM
A Look at Whether AbbVie (ABBV) Could Eventually Face the Same Issues as Gilead (GILD) 2/17/2017 6:36:22 AM
Amygdala Acquires GS-6637 From Gilead (GILD) 2/16/2017 8:20:39 AM
Gilead (GILD) Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya For Treatment Of HIV-1 In Treatment-Na├»ve Adults 2/15/2017 6:29:39 AM
Bristol-Myers Squibb (BMY) Could Finally Go on the Market; Rumored Suitors Include Gilead (GILD), Pfizer (PFE), Novartis AG (NVS) and Roche (RHHBY) 2/14/2017 10:38:25 AM
Gilead (GILD) Presents New Phase II Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV 2/14/2017 6:38:15 AM
Gilead (GILD) Announces Findings From New Preclinical Study Evaluating Novel Class Of HIV Capsid Inhibitors 2/14/2017 6:36:39 AM
Gilead (GILD) Looks Over Its Shoulder as GlaxoSmithKline (GSK) Gains Ground With New HIV Phase III Trial Data 2/14/2017 5:52:26 AM